Scott Garrett

Scott is Vice President, Commercial Strategy. He brings over 30 years of experience across Marketing, Analytics, Product Development, Health Economics, Sales and Alliance Management, with a focus on driving success in high-growth first-launch companies spanning BioPharma, MedTech and Diagnostics. Most recently, Scott served as Vice President of Commercial Strategy at Turning Point Therapeutics, a precision oncology company acquired by Bristol Myers Squibb. Prior to this, he held leadership roles at Portola Pharmaceuticals (acquired by Alexion), Cadence Pharmaceuticals (acquired by Mallinckrodt) and CV Therapeutics (acquired by Gilead). Earlier in his career he held Sales, Marketing, and Product Development roles at Scios Inc. (acquired by Johnson & Johnson), Boston Scientific, and Nycomed Amersham (now GE Healthcare). Scott holds a Bachelor of Science in Marketing from San Diego State University and an MBA from the University of California, Irvine.